Real-world clinical data provider Atropos Health has announced that it will be making its Commercial Analytics solutions available to life science leaders. This new offering will harness the speed, accuracy, and efficiency of the company’s AI-powered ChatRWD® application—providing users with the ability to generate rapid answers to medical questions alongside actionable insights. Use cases supported by this technology for life science leaders include market sizing & segmentation, prescription trends, HCP and account targeting, patient journeys, market share, and much more.
Atropos Health CEO and Co-Founder Dr. Brigham Hyde expressed his enthusiasm with the company’s announcement, stating, “The Commercial Analytics solution is a natural progression from our solutions for RWE and Precision Medicine. Building off our clinical grade quality and accuracy, we are expanding the type of questions and use cases biopharma users can ask and making available our ever-expanding Atropos Evidence™ Network to ensure the right data is being used for every analysis.”
President and Head of Product Neil Sanghavi added further context for this news in the company’s press release, saying, “With the basis of a product built upon point of care and clinical decision use cases, we are able to now extend the use of RWD to more applications that can reduce the time from symptom to treatment. Commercial and brand leaders require high quality data to make decisions about where to deploy resources and the Atropos Health Commercial Analytics solution provides faster access to data to inform those decisions.”
Founded in 2020 and based out of Palo Alto, California, Atropos Health has quickly made a name for itself operating across 18 clinical specialties with its Rapid Analytics, On-Demand Insights, and Evidence-Based Care offerings. For more information about this announcement, read the Atropos Health press release below.
See related materials: